Les Laboratoires Servier SAS - Company Profile
Powered by 
All the data and insights you need on Les Laboratoires Servier SAS in one report.
$295
- Save hours of research time and resources with
our up-to-date Les Laboratoires Servier SAS Strategy Report
- Understand Les Laboratoires Servier SAS position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Les Laboratoires Servier SAS (Servier) researches, develops, manufactures, and markets drugs for treating various diseases. The company's portfolio of marketed products treats central nervous system (CNS) disorders, cardiovascular diseases, cancer, ENT disorders, respiratory diseases, hematological disorders, hormonal disorders, and others. The company also provides generic drugs and contract development and manufacturing services across its global network. The company also provides digital therapeutic solutions through its e-health division, WeHealth Digital Medicine. It sells products in Europe, America, Middle East, Africa, and Asia. Servier headquartered in Suresnes, Ile-de-France, France.
Headquarters
France
Address
50 Rue Carnot, Suresnes, Ile-de-France, 92284
Website
www.servier.com
No of Employees
21,400
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$5.2B
Les Laboratoires Servier SAS premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Branded and Generic Drugs: | Contract Development and Manufacturing Services | Hyperium |
| Ear Nose Throat Disorders | Preterax | |
| Oncology | Coversyl | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In May, the company entered into an agreement with Aitia to create new Gemini Digital twins to help in the fight against Pancreatic Cancer. |
| 2023 | Contracts/Agreements | In April, the company entered into an agreement with Specifica and Symphogen A/S for the development of drugs in particular in oncology, neuroscience and immune-inflammation. |
| 2023 | Contracts/Agreements | In April, the company entered into an agreement with Luxna Biotech Co., Ltd. for drug discovery research in the field of neurological diseases. |
Competitor Comparison
| Key Parameters | Les Laboratoires Servier SAS | Pfizer Inc | Sanofi | Ipsen SA | Laboratoires Pierre Fabre SA |
|---|---|---|---|---|---|
| Headquarters | France | United States of America | France | France | France |
| City | Suresnes | New York | Paris | Boulogne-Billancourt | Castres |
| State/Province | Ile-de-France | New York | Ile-de-France | Bourgogne | - |
| No. of Employees | 21,400 | 83,000 | 91,573 | 5,072 | 9,600 |
| Entity Type | Private | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Olivier Laureau | Chief Executive Officer; President | Senior Management | 2014 | - |
| Claude Bertrand | Chief Scientific Officer; Executive Vice President - Research and Development | Senior Management | 2018 | - |
| Pierre Venesque | Executive Vice President - Industry | Senior Management | 2019 | - |
| Philippe Gonnard | Executive Vice President - Global Product Strategy | Senior Management | 2023 | - |
| David Hindley | Executive Vice President - Human Resources | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward